Pheon Therapeutics

About Pheon Therapeutics

Pheon Therapeutics is a leading specialist in Antibody-Drug Conjugates (ADCs), focused on developing next-generation ADCs to treat a wide range of hard-to-treat cancers, particularly solid tumors. Their mission is to transition their lead asset into clinical development while building a proprietary pipeline to address unmet medical needs in oncology.

Products & Services

Next-Generation ADCs:A pipeline of novel Antibody-Drug Conjugates targeting difficult-to-treat solid tumors using monoclonal antibodies against novel and validated targets, combined with proprietary payload platforms or off-the-shelf linker payload combinations.

Specialties

Antibody-Drug Conjugates (ADCs) Oncology Solid Tumor Treatment ADC Engineering

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 120000000 MR: - FA: $120m FAN: 120000000	D: 2024-05-21 FD: 2024-05-21	8 investors

Series B Latest

2024-05-21

$120.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeff Albers

Chairman

C

Cyrus Mozayeni

Chief Executive Officer

E

Enoch Kariuki

Non-Executive Director

S

Samuel C. Blackman

Non-Executive Director

M

Michael Gladstone

Partner at Atlas Venture

S

Shaun A. Kirkpatrick

President, Biotechnologies

View 14 more team members with Pro

Unlock Full Team Directory

Recent News